Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence

Colorectal Disease

Volumn 7, Issue 4, 2005, Pages 382-386

  Alexander Sefre, F ^b   Chandrakumaran, K ^a   Banerjee, S ^a   Sexton, R ^a   Thomas, J M ^c   Cecil, Tom ^a   Moran, Brendan ^a  

^a NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Carcinoembryonic antigen; Cytoreduction; Pre operative tumour markers; Pseudomyxoma peritonei; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; MITOMYCIN C; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; MALE; PERITONEUM PSEUDOMYXOMA; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PSEUDOMYXOMA PERITONEI; TUMOR MARKERS, BIOLOGICAL;

EID: 21244477557     PISSN: 14628910     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2005.00773.x     Document Type: Article

References (29)

1. Sugarbaker PH, Ronnett BM, Archer A et al. Pseudomyxoma peritonei syndrome. Adv Surg 1996; 30: 233-80.
2. Sugarbaker PH. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6: 727-31.
3. Sugarbaker PH. (1998) Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. A Manual for Physicians and Nurses, 3rd edn. Ludann Co, Grand Rapids.
4. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29-42.
5. Glehen O, Mithieux F, Osinsky D et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Onc 2003; 21: 762-4.
6. Sulkin TV, O'Neill H, Amin AI, Moran B. CT in pseudomyxoma peritonei. a review of 17 cases. Clin Radiol 2002; 57: 608-13.
7. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002; 22: 2311-6.
8. Lai IR, Lee WJ, Huang MT, Lin HH. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 2002; 49: 1157-60.
9. Gattani AM, Mandeli J, Bruckner HW. Tumor markers in patients with pancreatic carcinoma. Cancer 1996; 78: 57-62.
10. Gebauer G, Muller-Ruchholtz W. Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance. Anticancer Res 1997; 17: 2939-42.
11. Midiri G, Amanti C, Consorti F et al. Usefulness of preoperative CEA levels in the assessment of colorectal cancer patient stage. J Surg Oncol 1983; 22: 257-60.
12. Wolmark N, Fisher B, Wieand HS et al. The prognostic significance of preoperative CEA levels in colorectal cancer. Results from NSABP clinical trials. Ann Surg 1984; 199: 375-81.
13. Steele G, Ellenburg S, Ramming K et al. CEA monitoring among patients in multi-institutional adjuvant GI therapy protocols. Ann Surg 1982; 196: 162-9.
14. Beatty JD, Romero C, Brown PW et al. Clinical value of CEA. Diagnosis, prognosis and follow up of the patients with cancer. Arch Surg 1979; 114: 563-7.
15. van der Burg ME, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990; 1: 301-2.
16. Krebs HB, Goplerud DE, Kilpatrick SJ et al. Role of CA 125 as tumor marker in ovarian cancer. Obstet Gynecol 1986; 67: 473-7.
17. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001; 91: 490-5.
18. Kochi M, Fujii M, Kanamori N et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer 2000; 3: 177-86.
19. Chao Xu Zheng, Wen Hua Zhan, Ji Zong Zhao et al. The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer. World J Gastroenterol 2001; 3: 431-4.
20. Zoetmulder PA, Sugarbaker PH. Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Eur J Cancer 1996; 32A: 1727-33.
21. Sugarbaker PH, Chang D, Koslowe P. Peritoneal carcinomatosis from appendiceal cancer: a paradigm for treatment of abdomino-pelvic dissemination of gastrointestinal malignancy. Acta Chir Austriaca 1996; 28: 4-8.
22. Landen S, Bertrand C, Maddern GJ et al. Appendiceal mucoceles and pseudomyxoma peritonei. Surg Gynecol Obstet 1992; 175: 401-4.
23. Sasano H, Shizawa S, Nagura H, Yamaki T. Mucinous adenocarcinoma arising in a giant urachal cyst associated with pseudomyxoma peritonei and stromal osseous metaplasia. Pathol Int 1997; 47: 502-5.
24. van Ruth S, Hart AA, Bonfrer JM, Verwaal VJ, Zoetmulder FA. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002; 9: 961-7.
25. Nast MF, Kemp GM, Given PT Jr. Pseudomyxoma peritonei: treatment with intraperitoneal 5-fluorouracil. Eur J Gynaecol Oncol 1993; 14: 213-7.
26. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125 levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001; 10: 489-93.
27. Behbehani AI, Mathew A, Farghaly M, van Dalen A. Reference levels of the tumor markers carcinoembryonic antigen, the carbohydrate antigens 19-9 and 72-4, and cytokeratin fragment 19 using the Elecsys Relecsys 1010 analyzer in a normal population in Kuwait. The importance of the determination of local reference levels. Int J Biol Markers 2002; 17: 67-70.
28. Gough DB, Donohue JR, Schutt Alet al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219: 112-9.
29. Wertheim I, Pleischhacker D, McLachlin CM, Rice LW, Berkowitz RS, Goff BA. Pseudomyxoma peritonei. a review of 23 cases. Obstet Gynecol 1994; 84: 17-21.